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Background: Exposure to second-hand tobacco smoke (SHS) is one of the prime risk factors for chronic lung
disease development. Smoking during pregnancy may lead to birth defects in the newborn that include pulmonary
dysfunction, increased susceptibility to opportunistic pathogens, or initiation of childhood respiratory manifestations
such as bronchopulmonary dysplasia (BPD). Moreover, exposure to SHS in early childhood can have negative
impact on lung health, although the exact mechanisms are unclear. Autophagy is a crucial proteostatic mechanism
modulated by cigarette smoke (CS) in adult lungs. Here, we sought to investigate whether SHS exposure impairs
autophagy in pediatric lungs.
Methods: Pregnant C57BL/6 mice were exposed to room air or SHS for 14 days. The newborn pups were
subsequently exposed to room air or SHS (5 h/day) for 1 or 14 days, and lungs were harvested. Soluble and
insoluble protein fractions isolated from pediatric mice lungs were subjected to immunoblotting for ubiquitin (Ub),
p62, VCP, HIF-1α, and β-actin.
Results: Our data shows that short-term exposure to SHS (1 or 14 days) leads to proteostasis and autophagy-
impairment as evident by significant increase in accumulation of ubiquitinated proteins (Ub), p62 (impaired-
autophagy marker) and valosin-containing protein (VCP) in the insoluble protein fractions of pediatric mice lungs.
Moreover, increased HIF-1α levels in SHS-exposed mice lungs points towards a novel mechanism for SHS-induced
lung disease initiation in the pediatric population. Validating the in vivo studies, we demonstrate that treatment of
human bronchial epithelial cells (Beas2b cells) with the proteasome inhibitor (MG-132) induces HIF-1α expression
that is controlled by co-treatment with autophagy-inducing drug, cysteamine.
Conclusions: SHS-exposure induced proteostasis/autophagy impairment can mediate the initiation of chronic lung
disease in pediatric subjects. Hence, our data warrants the evaluation of proteostasis/autophagy-inducing drugs,
such as cysteamine, as a potential therapeutic intervention strategy for SHS-induced pediatric lung diseases.
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Second-hand cigarette smoke (SHS) is a major environ-
mental risk factor affecting the pediatric population.
Over five decades ago, it was discovered that cigarette
smoking during pregnancy impacts fetal development
leading to premature birth and other birth defects [1, 2].
However, a recent study from the UK showed that
mothers exposed to SHS also demonstrate an increased
risk of early delivery and reduced birth weight of infants
[3]. Gestational SHS exposure is known to induce irre-
versible hypoalveolarization and decreased angiogenesis,
and lung secretory function, leading to bronchopulmon-
ary dysplasia (BPD). Moreover, children exposed to SHS
during their early phases of development are more
susceptible to infections that may trigger inflammation
and promote BPD pathogenesis. Although, underlying
mechanisms and outcomes of BPD are not thoroughly
investigated in the pediatric population.
Cigarette smoke (CS) is known to modulate the
ubiquitin-proteasome pathway that is crucial in maintain-
ing proteostasis [4, 5]. The initial CS-mediated activation
of the ubiquitin-proteasome pathway triggers the unfolded
protein response so that misfolded proteins can be either
recycled, folded properly, or degraded. However, chronic-
CS exposure induces the accumulation of insoluble ubi-
quitinated proteins, at rates faster than the proteasome is
able to degrade them. Moreover, sequestosome-1/p62, a
marker for autophagy impairment, is elevated in chronic
smokers [6, 7] and its accumulation in the insoluble frac-
tion indicates its localization to aggresome-bodies [6, 7].
Valosin-containing protein (VCP) can facilitate degrad-
ation of misfolded proteins but its accumulation in aggre-
some-bodies on CS exposure [6] impairs both autophagy
and proteostasis mediated clearance of misfolded proteins.
CS exposure is known to induce hypoxia inducible
factor-1 (HIF-1α) expression in murine and rabbit lungs.
Briefly, HIF-1α is a transcription factor that mediates pul-
monary response to hypoxia as its expression is closely
regulated by oxygen concentration, which is largely respon-
sible for the HIF-1α transcriptional activity [8, 9]. Hence,
CS-induced HIF-1α expression contributes to the patho-
genesis of chronic obstructive pulmonary disease (COPD)
[8] and therefore can also play a role in the development of
BPD. Interestingly, overexpression of HIF-1α in the embry-
onic pulmonary epithelium leads to impaired branching
morphogenesis and decreased epithelial cell proliferation,
which negatively impacts lung maturation [10]. This im-
pairment of lung maturation when coupled with mechan-
ical ventilation post-premature birth is thought to promote
the susceptibility of such a patient population to develop
BPD [11]. Thus, we designed this preliminary study to
identify the effects of CS/SHS on HIF-1α expression, pro-
teostasis/autophagy, and its potential impact on develop-
ment of pediatric lung disease(s) such as BPD.Correspondence/Findings
Briefly, we used a pediatric and neonatal murine model to
identify the effects of CS/SHS exposure on proteostasis/
autophagy and HIF-1α expression as a potential mechan-
ism for development of BPD-like pulmonary dysfunction
in the pediatric population.
Methods
Mice SHS exposure
All animal experiments were performed following our Insti-
tutional (JHU and CMU) Animal Care & Use Committee
(IACUC) protocols. Pregnant C57BL/6 mice were exposed
to room air or SHS for 5 h/day for 14 days as we have pre-
viously described in detail [12]. After delivery, the pediatric
mice were similarly exposed to either room air or SHS for
one day, and likewise, another group was exposed to either
conditions for 14 days. After the respective exposures, the
mice were sacrificed and the pediatric lungs were harvested
for further analysis by immunoblotting.
Western blot analysis
After room air and SHS exposure, the lung tissues were
harvested and lysates were prepared using RIPA buffer
(25 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS) containing 1× pro-
tease inhibitor cocktail (Pierce). Lung tissues were ho-
mogenized and sonicated on ice for 3–5 min and with
10–15 s pulses, respectively. The Bradford Protein Assay
Kit was used to quantify the amount of protein in the
total protein lysates. Soluble and insoluble protein frac-
tions were separated by centrifugation at 13,000 rpm for
15 min at 4 °C. Soluble (50 μg) and/or insoluble protein
fractions (pellet, isolated from equal amount of protein
500 μg, for each sample) were separated on 10% SDS-
PAGE and transferred to 0.45 μm nitrocellulose mem-
branes (Bio-Rad) for immunoblotting. The membranes
were blocked with 1% nonfat dry milk at room
temperature for 1 h on a rotary shaker, followed by over-
night incubation at 4 °C with mouse monoclonal ubiqui-
tin (1:1000; Santa Cruz), rabbit polyclonal p62 (1:500;
Santa Cruz), rabbit polyclonal VCP (1:500; Santa Cruz),
rabbit polyclonal HIF-1α (1:500; Santa Cruz), and mouse
monoclonal β-actin (1:5000; Sigma) as primary antibodies.
The membranes were washed (3×) with a PBS-Tween
buffer (0.5% tween-20 in 1× PBS) and incubated with
1:6000 goat horseradish peroxidase-conjugated anti-
mouse antibody (Novus Biologicals) or 1:6000 goat horse-
radish peroxidase-conjugated anti-rabbit antibody (Novus
Biologicals) for 1 hr at room temperature, followed by 3×
washes with PBS-tween buffer as described above. The
Clarity™ Western ECL substrate (Bio-Rad) was used for
chemiluminescence detection of immunoblots using a LI-
COR C-DiGit™ Blot Scanner. Images captured with Image
Studio Lite 5.0, and ImageJ 1.49o (NIH) software
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by densitometry analysis and using β-actin (soluble
fraction) as the loading control.
In vitro experiments
The human bronchial epithelial cells (Beas2b cells) were
cultured using standard cell culture conditions as recently
described [13]. The cells were plated in six well plates and
treated with MG-132 (5 μM) and/or cysteamine (250 μM)
for 12 h. Cell lysates were prepared using the RIPA buffer,
and equal amount of total protein was separated on a 10%
SDS-PAGE and transferred to 0.45 μm nitrocellulose
membranes (Bio-Rad) for immunoblotting as described
above. Briefly, the membranes were immunoblotted for
HIF-1α (rabbit polyclonal; 1:500; Santa Cruz) or β-actin
(mouse monoclonal;1:5000; Sigma) primary antibodies
followed 1:6000 goat horseradish peroxidase-conjugated
anti-mouse antibody (Novus Biologicals) or 1:6000 goat
horseradish peroxidase-conjugated anti-rabbit antibody
(Novus Biologicals).
Results
Second-hand cigarette smoke (SHS) exposure causes
proteostasis/autophagy impairment in neonatal mice lungs
We have recently shown that tobacco-smoke, e-cigarette
vapor (eCV), and/or inhaled-nicotine exposure inducesFig. 1 SHS exposure induces autophagy-impairment in pediatric and neon
accumulation of ubiquitinated proteins (ubiquitin, Ub), p62 (sequestosome-1
in the soluble and/or insoluble lung protein-fractions isolated from SHS (CS) o
(P14), post-delivery. The mothers of these pups were also exposed to SHS for
of soluble Ub, VCP, p62, and HIF-1α normalized to β−actin. d Bar graph of rela
soluble β-actin. (*p < 0.05; **p < 0.01)proteostasis/autophagy impairment as a central mechan-
ism for pathogenesis of COPD-emphysema [4, 6, 7, 14].
Hence, we were interested in evaluating this as a poten-
tial mechanism of SH tobacco-smoke exposure on the
pediatric population.
Here, we report that SHS exposure of pregnant mice
(14 days) followed by exposure to the pups (either 1 or
14 days), leads to significant (p < 0.05) accumulation of
ubiquitinated proteins in the soluble and insoluble protein
fractions of pediatric mice lungs, as compared to room air
(RA) exposed mice, indicating early initiation of autoph-
agy-impairment (Fig. 1a–d, p < 0.05). The data further in-
dicates that 14 days of SHS exposure to neonatal mice
induces higher accumulation of ubiquitinated proteins in
the insoluble protein fraction as compared to 1-day expos-
ure (Fig. 1c, d), implying increase in proteostasis and/or
autophagy-impairment in 14-day-exposed mice lungs.
We have shown earlier that autophagy-impairment
leads to accumulation of VCP and p62 in the insoluble
protein fractions (aggresome bodies) [6, 7]. In accord
with previous findings, here, we report that both day 1
and 14-SHS-exposure groups of mice show significantly
higher p62 protein levels (insoluble), and a moderate in-
crease in VCP in the insoluble protein fraction as com-
pared to room air control (Fig. 1c, d), suggesting
autophagy-impairment.ate murine lungs mice lungs. a, c Western blots showing the
), VCP (valosin containing protein), and HIF-1α (hypoxia inducible factor)
r room air (RA)—exposed neonatal mice sacrificed at day 1 (P1) or 14
the last 14 days of the pregnancy. b Bar graph of relative optical density
tive optical density of insoluble Ub, VCP, and p62 is also normalized to
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observed in 1-day-SHS exposed mice compared to 1-day
room air control (p < 0.05). Moreover, after 14 days of
SHS exposure, there is even more significant (p < 0.05)
change in HIF-1α as compared to 14-day room air con-
trols. Data suggests that HIF-1α may be elevated to con-
trol the acute response to SHS exposure. Previous
studies have shown that HIF-1α is degraded via the
ubiquitin-proteasome system [15]. We also observed a
significant increase in HIF1-α levels in Beas2b cells upon
proteasome inhibition using MG-132, which was re-
stored by treatment with an autophagy-inducing drug,
cysteamine (Fig. 2a, b, p < 0.05), indicating that HIF-1α
levels could be modulated by proteostasis/autophagy im-
pairment. Overall, these findings suggest that even acute
exposure to SHS during pregnancy (14 days; day 1Fig. 2 Proteasome inhibition induced HIF-1α level is controlled by autopha
in HIF-1α expression in total protein lysates isolated from Beas2b cells treated
(mean ± SEM, n = 3) indicates that MG-132 treatment significantly elevates HIF
drug, cysteamine. (**p < 0.01; ***p < 0.001)group) may lead to the impairment of crucial proteosta-
sis/autophagy mechanisms potentially rendering the
neonate/pediatric population more susceptible to pul-
monary diseases such as BPD.
Discussion
We report here that similar to the deleterious effects of
SHS exposure on adult pulmonary function, acute SHS
exposure of pediatric mice born after an in utero SHS
exposure (14 days during pregnancy) can potentially lead
to initiation of lung disease via autophagy-impairment
mediated aggresome formation that is known to pro-
mote the pathogenesis of chronic obstructive lung dis-
ease (Fig. 3) [6, 7].
Our preliminary results show that proteostasis/autoph-
agy impairment caused by SHS occurs as early as daygy inducing drug, cysteamine. a, b Western blots showing the changes
with MG-132 (5 μM) and/or cysteamine (250 μM) for 12 h. The data
-1α levels that were reduced by co-treatment with autophagy-inducing
Fig. 3 Schema showing novel mechanism for SHS-induced pediatric lung dysfunction. Exposure to SHS during early lung development (neonates/
pediatric population) may potentiate initiation of chronic lung disease via oxidative stress mediated proteostasis/autophagy impairment and/or induction
of HIF-1α levels. Therapeutic intervention using proteostasis/autophagy inducing drugs may mitigate the SHS exposure-mediated pathogenic changes
initiating pediatric lung diseases such as bronchopulmonary dysplasia (BPD) or adult COPD-emphysema-like childhood condition
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defect may have severe consequences on the develop-
ment of the lungs and can lead to pediatric lung condi-
tions, such as BPD. We have previously shown that an
early age-related (pediatric vs adult) decline in proteos-
tasis augments NFκB-mediated inflammation; Pa-LPS-
induced acute lung injury (ALI) and sepsis [16]. SHS
exposure in young children can similarly initiate an early
decline in proteostasis in developing lungs, thus increas-
ing the susceptibility to pulmonary exacerbations. SHS is
also known to induce acquired-cystic fibrosis transmem-
brane conductance regulator (CFTR) dysfunction via
proteostasis/autophagy impairment [17] but the under-
lying mechanisms and outcomes are not thoroughly in-
vestigated in the pediatric population and represent a
future area of study. Since cystic fibrosis (CF) is a known
pediatric genetic disease, there is emphasis on the need
to evaluate SHS-induced acquired-CF in preterm/
pediatric patients. A few recent studies demonstrate that
modulating proteostasis could help in the rescue of themisfolded ΔF508-CFTR protein [18] thus highlighting
the therapeutic potential of proteostasis augmentation in
cystic fibrosis lung disease [19, 20]. Furthermore, SHS
impairs bacterial phagocytosis in macrophages by dimin-
ishing CFTR expression in the lipid rafts, resulting in in-
creased susceptibility to infections [17]. Thus, SHS-
induced prolonged infection and an exaggerated inflam-
matory response may facilitate the initiation of chronic
lung diseases in pediatric subjects.
Moreover, deficiency of membrane CFTR also causes
autophagy-impairment via induction of reactive oxygen
species (ROS) [12], leading to peri-nuclear accumulation
of damaged/misfolded proteins in aggresome-bodies, as
seen by the accumulation of ubiquitinated proteins, p62
and VCP in the insoluble fraction, which may mediate
COPD-like symptoms or BPD in pediatric subjects. Dur-
ing fetal development, baseline autophagy is associated
with maintenance of healthy pregnancy, while autoph-
agy-impairment can promote preterm delivery [2]. This
may explain the higher susceptibility of preterm infants
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is essential for clearance of common lung pathogens like
Pseudomonas aeruginosa (Pa). Hence, restoring autophagy-
impairment may be a lucrative therapeutic strategy to
alleviate COPD-like symptoms and prevent BPD in SHS-
exposed infants.
The underlying mechanism(s) of in utero SHS-
induced alterations in airway physiology is yet to be
studied and may involve proteostasis-mediated modula-
tion of surfactant proteins, NFκB and growth factors.
Specifically, SHS is known to induce NFκB levels by
regulating proteasomal degradation of its endogenous
inhibitor, IκB [21], which is anticipated as the potential
mechanism for NFκB induction in BPD, similar to its
role in other diseases states such as COPD, cystic fibro-
sis (CF), etc. In BPD, NFκB is also known to inhibit ex-
pression of fibroblast growth factor (FGF-10) that is
essential for branching and morphogenesis of the con-
ducting airways of the lungs [22]. NFκB induction, via
SHS exposure, can reduce FGF-10 expression in preterm
infants promoting initiation of BPD [23].
Altered expression of other common growth factors
such as vascular endothelial growth factor (VEGF) and
epidermal growth factor (EGF) are also associated with
BPD pathogenesis and are regulated by autophagy mech-
anisms [22]. VEGF is a known potent mitogen for the
induction of vascularity, and its expression is downregu-
lated in BPD that may decrease nitric oxide (NO) levels,
which is known to promote angiogenesis during lung
development [22, 24]. Interestingly, SHS is known to
decrease VEGF and NO production, while autophagy in-
duction, specifically, autophagy related protein-7 (Atg7),
enhances NO production by the JAK/STAT pathway,
which may promote normal lung development [25]. An-
other growth factor, EGF, essential for lung development
is overexpressed in BPD, which then adversely impacts
alveolar septa-formation [23]. Moreover, EGF has been
shown to inhibit autophagy that can impact lung devel-
opment by changing levels of NO. In fact, HIF-1α ex-
pression is acutely modulated by the epidermal growth
factor (EGF) receptor-mediated cell signaling [26]. The
early elevation of HIF-1α in our model may be explained
by the SHS-induced EGF. EGF is also essential for lung
development and is overexpressed in BPD, which then
adversely impacts alveolar septa-formation [23], further
supporting our hypothesis regarding the mechanism for
SHS-induced BPD (Fig. 3).
There is a paucity of information regarding the mecha-
nisms by which SHS-mediated proteostasis impairment
induces variety of pediatric lung diseases. Our data
shows the extent of SHS exposure-induced proteostasis/
autophagy impairment that can occur post-delivery at a
very young age. Hence, further research is warranted to
validate the potential benefits of proteostasis/autophagyregulators in mitigating SHS-induced inflammatory apop-
totic stress responses, pulmonary exacerbations, and/or
chronic lung diseases in infants and preterm babies.
Implications
Chronic SHS exposure is known to impact normal lung
development via alterations in growth factors, and fre-
quent occurrence of acute respiratory problems, which
may lead to initiation of chronic lung disease. Our data
shows that even acute exposure to SHS in utero causes
proteostasis/autophagy impairment in the pediatric/neo-
nate murine lungs as a plausible mechanism to trigger
progression of chronic lung disease(s). Thus, restoring
proteostasis/autophagy could be of potential therapeutic
advantage for SHS-mediated pediatric lung disease(s) in
pediatric/neonate subjects.
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